CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line treatment for HR-positive/HER2-negative advanced breast cancer and have significantly improved patient outcomes. However, in real-world clinical practice, a subset of patients still experiences rapid disease progression early during treatment, suggesting the presence of more aggressive tumor biology and potential intrinsic endocrine resistance mechanisms.

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.

On May 8, local time, at the ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Jian Zhang from Fudan University Shanghai Cancer Center delivered a rapid oral presentation of efficacy and safety results from the Phase II expansion cohort evaluating the PD-L1×VEGF-A bispecific antibody Pumitamig in combination with the TROP2 antibody-drug conjugate (ADC) BNT325 (sacituzumab drozuntecan) as first-line treatment for advanced or metastatic triple-negative breast cancer (a/mTNBC) (NCT05438329).

Trastuzumab deruxtecan (T-DXd) has dramatically reshaped the treatment landscape for advanced HER2-positive breast cancer because of its outstanding efficacy. It is now considered the standard second-line treatment for HER2-positive advanced breast cancer and has also demonstrated remarkable activity in both the first-line metastatic and early breast cancer settings.

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Yongsheng Wang from Shandong Cancer Hospital delivered a presentation entitled “Precision Decision-Making in Sentinel Lymph Node Biopsy”, offering an in-depth discussion on management strategies and individualized decision pathways for sentinel lymph node biopsy (SLNB).

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Jiong Wu from Fudan University Shanghai Cancer Center (FUSCC) delivered a featured presentation on the “FUSCC Model of Autologous Breast Reconstruction,” systematically outlining his center’s distinctive framework and standardized training pathway for autologous tissue breast reconstruction.

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on oncoplastic breast-conserving surgery and breast reconstruction techniques.

From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.

Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.

During the 2026 National Breast Cancer Conference, Professor Michael Gnant, President of the St. Gallen International Breast Cancer Conference (SGBCC), traveled across continents to participate in the event, further deepening collaboration between SGBCC and the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC).